We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Allergan plc | NYSE:AGN | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
From May 2019 to May 2024
By Pietro Lombardi
The European Commission has approved with conditions the planned $63 billion acquisition of Allergan PLC (AGN) by AbbVie Inc. (ABBV).
The decision came after AbbVie proposed to sell the rights to Allergan's brazikumab--a therapy that is under development--to assuage the Commission's concerns, the Commission said Friday. The approval is conditional on this divestment.
The European authorities' investigation focused on treatments for inflammatory bowel diseases, an area where the drug makers' activities overlap.
"Inflammatory bowel diseases are lifelong conditions with devastating effects on the life of millions of people," Executive Vice President Margrethe Vestager said.
"Our decision makes sure that the merger between AbbVie and Allergan will not disrupt the development of a promising innovative treatment for these diseases. This will increase the choice of treatments and offer better prices for patients."
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
January 10, 2020 09:59 ET (14:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
